曲美他嗪联合托拉塞米对心力衰竭患者心肌重塑及血浆BNP水平的影响

Effects of Trimetazidine Combined with Tolasemide on Myocardial Remodeling and Plasma BNP Level in Patients with Heart Failure

目的:探讨曲美他嗪联合托拉塞米对心力衰竭患者心肌重塑及血浆BNP水平的影响。方法:选取2017年1月-2018年10月本院收治的心力衰竭患者126例,根据临床治疗药物不同将其分为研究组和对照组,每组36例。对照组采用托拉塞米治疗,研究组采用曲美他嗪联合托拉塞米治疗。比较两组临床疗效、血浆脑钠肽(BNP)水平、左室射血分数(LVEF)、左室收缩末期容积(LVSDV)、左室舒张末期容积(LVEDV)、左室舒张末期内径(LVEDd)、平均动脉压(MAP)、心率(HR)、心肌能量消耗(MEE)、左心室质量指数(LVMI)、左心室质量(LVM)、左室收缩末期内径(LVIDs)、心功能分级。结果:研究组治疗总有效率为95.2%,高于对照组的81.0%,差异有统计学意义(P<0.05)。治疗3、6个月,研究组BNP水平均低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组LVEF高于对照组,LVSDV、LVEDV、LVEDd、MAP、HR均低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组MEE、LVMI、LVM、LVIDs均低于对照组,差异均有统计学意义(P<0.05)。结论:应用曲美他嗪联合托拉塞米治疗心力衰竭效果显著,值得推广。

Objective:To explore the effects of Trimetazidine combined with Torasemide on myocardial remodeling and plasma BNP levels in patients with heart failure.Method:A total of 126 patients with heart failure admitted to our hospital from January 2017 to October 2018 were selected.They were divided into study groups and control groups according to the clinical treatment drugs,36 cases in each group.The control group was treated with Torasemide,the study group was treated with Trimetazidine combined with Torasemide.The clinical efficacy,plasma brain natriuretic peptide(BNP)level,left ventricular ejection fraction(LVEF),left ventricular end-systolic volume(LVSDV),left ventricular end-diastolic volume(LVEDV),and left ventricular end-diastolic diameter(LVEDd),mean arterial pressure(MAP),heart rate(HR),myocardial energy expenditure(MEE),left ventricular mass index(LVMI),left ventricular mass(LVM),left ventricular end systolic diameter(LVIDs)and grade of cardiac function were compared between the two groups.Result:The total effective rate in the study group was 95.2%,higher than 81.0%of the control group,the difference was statistically significant(P<0.05).3 and 6 months after treatment,the level of BNP in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,LVEF in the study group was higher than that in the control group,LVSDV,LVEDV,LVEDd,MAP and HR in the study group were all lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the MEE,LVMI,LVM and LVIDs in the study group were all lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:The application of Trimetazidine and Torasemide in the treatment of heart failure is significant and worthy of promotion.